Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models()

Antiangiogenic therapy has shown promising results in preclinical and clinical trials. However, tumor cells acquire resistance to this therapy by gaining ability to survive and proliferate under hypoxia induced by antiangiogenic therapy. Combining antiangiogenic therapy with hypoxia-activated prodru...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Sushil, Sun, Jessica D., Zhang, Libo, Mokhtari, Reza Bayat, Wu, Bing, Meng, Fanying, Liu, Qian, Bhupathi, Deepthi, Wang, Yan, Yeger, Herman, Hart, Charles, Baruchel, Sylvain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2018
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6041570/
https://www.ncbi.nlm.nih.gov/pubmed/29803017
http://dx.doi.org/10.1016/j.tranon.2018.05.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6041570/
https://www.ncbi.nlm.nih.gov/pubmed/29803017
http://dx.doi.org/10.1016/j.tranon.2018.05.004

Ejemplares similares